FDA Oncology Announcements

Anti-VEGFR × Gastrointestinal × Clear all

8 Announcements

FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer

Trial: SUNLIGHT
Drugs: LONSURF (trifluridine and tipiracil) · Fluoropyrimidine, bevacizumab · Anti-VEGFR antibody
Condition: Gastrointestinal

FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Trial: IMbrave150
Drugs: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, AVASTIN (bevacizumab) · Anti-VEGFR antibody
Condition: Gastrointestinal

FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Trial: IMbrave150
Drugs: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, AVASTIN (bevacizumab) · Anti-VEGFR antibody
Condition: Gastrointestinal

FDA approves ramucirumab for hepatocellular carcinoma

Trial: REACH-2
Drug: CYRAMZA (ramucirumab) · Anti-VEGFR antibody
Condition: Gastrointestinal

FDA approves first biosimilar for cancer treatment

Drugs: Mvasi (bevacizumab-awwb) · Anti-VEGFR antibody, Avastin (bevacizumab) · Anti-VEGFR antibody
Condition: Gastrointestinal

Ramucirumab in combination with paclitaxel

Drugs: Cyramza (ramucirumab) · Anti-VEGFR antibody, paclitaxel · Taxane
Condition: Gastrointestinal

Ramucirumab

Drug: Cyramza (ramucirumab) · Anti-VEGFR antibody
Condition: Gastrointestinal

Bevacizumab

Drug: Avastin (bevacizumab) · Anti-VEGFR antibody
Condition: Gastrointestinal